Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is N/A as of 2026-10-06T21:12:41.278Z.
Calculation as of: 2026-10-06T21:12:41.278Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$978.09M
EV/Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
EV/Assets Ratio
2.40x
TTM Avg
3.59x
3Y Avg
2.22x
5Y Avg
1.85x
Market Cap
$973.93M
EV/Assets Ratio
0.95x
TTM Avg
1.00x
3Y Avg
1.03x
5Y Avg
1.35x
Market Cap
$982.46M
EV/Assets Ratio
1.95x
TTM Avg
1.37x
3Y Avg
1.36x
5Y Avg
1.36x
Market Cap
$992.14M
EV/Assets Ratio
1.84x
TTM Avg
1.96x
3Y Avg
0.66x
5Y Avg
0.74x
Market Cap
$996.65M
EV/Assets Ratio
1.77x
TTM Avg
2.57x
3Y Avg
5.48x
5Y Avg
5.04x
Market Cap
$998.69M
EV/Assets Ratio
2.53x
TTM Avg
1.79x
3Y Avg
1.27x
5Y Avg
1.09x
Market Cap
$953.81M
EV/Assets Ratio
1.58x
TTM Avg
2.33x
3Y Avg
2.33x
5Y Avg
2.33x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 2.40x | 3.59x | 2.22x | 1.85x |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 0.95x | 1.00x | 1.03x | 1.35x |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 1.95x | 1.37x | 1.36x | 1.36x |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 1.84x | 1.96x | 0.66x | 0.74x |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 1.77x | 2.57x | 5.48x | 5.04x |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 2.53x | 1.79x | 1.27x | 1.09x |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | 1.58x | 2.33x | 2.33x | 2.33x |
| Savara Inc. (SVRA)vs › | $952.91M | 4.90x | 6.86x | 5.01x | 3.68x |
| Immatics N.V. (IMTX)vs › | $1.01B | 1.37x | 1.49x | 1.27x | 1.39x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
